GlassScriptPhysician profile
Sharyl R Brasher-Giles
NPI 1649286915
$42,234.28
in general payments reported to CMS, 2019-2025
23 companies · $854 in 2025
The $854 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $28K · 2021: $11K · 2022: $40.35 · 2023: $875 · 2024: $496 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.06 |
| Education | $383.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $39,457.45 | 2020-2021 | |
| Astellas Pharma US INC | $807.45 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $289.92 | 2023-2025 | Slynd |
| Abbvie INC. | $234.27 | 2021-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $207.27 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $169.39 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $143.48 | 2021-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Biogen, INC. | $104.81 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $103.90 | 2023-2024 | Twirla |
| Davol INC. | $102.02 | 2021 | |
| Lupin INC. | $98.90 | 2019 | |
| Shield Therapeutics INC | $87.27 | 2023-2024 | |
| Hologic INC | $81.27 | 2020 | |
| Pfizer INC. | $64.73 | 2023-2025 | |
| Organon LLC | $60.02 | 2023-2025 | Nexplanon |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $59.45 | 2023-2025 | |
| Therapeuticsmd, INC. | $29.63 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $29.39 | 2023 | Quviviq |
| Avanos Medical | $24.84 | 2020 | |
| Millicent US INC | $19.99 | 2025 | Femlyv |
| Mimedx Group, INC. | $19.67 | 2024 | |
| Channel Medsystems, INC. | $19.67 | 2023 | |
| Lsi Solutions INC | $19.49 | 2023 | Fornisee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharyl Brasher-Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.